What Was Chem-Med’s Rate Of Sales Growth In 2015? ✓ Solved

What was Chem-Med’s rate of sales growth in 2015?

Case Study: Chem-Med Company Overview

In April 2016, Dr. Nathan Swan, the CEO and founder of Chem-Med Company, grappled with the complexities of financial management alongside the challenges of leading a growing biotechnology firm. Established in 2001, Chem-Med had developed a proprietary process for isolating sodium hyaluronate (HA), leading to the production of two primary products, VISCAM and VISCHY, used in medical applications. The company faced competition from established players like Pharmacia, prompting legal actions over unfair trade practices. As Chem-Med sought to attract potential investors, Dr. Swan needed insights into the firm’s financial performance, growth potential, and market position. This case study will address key financial questions to evaluate Chem-Med’s attractiveness as an investment opportunity.

1. Chem-Med’s Rate of Sales Growth in 2015

Based on the provided income statement data, Chem-Med's sales figures for 2014 and 2015 were $3,051,000 and $3,814,000, respectively. To calculate the sales growth rate for 2015, we can use the following formula:

Sales Growth Rate = [(Sales Year 2 - Sales Year 1) / Sales Year 1] x 100%

Using the provided figures:

Sales Growth Rate = [(3,814 - 3,051) / 3,051] x 100% = 24.99%

For forecasting, if we look at past trends, Chem-Med might expect a sales growth rate of around 25% for 2016, tapering to 20% in 2017, and 15% in 2018, reflecting a gradual decline in growth expectations as the market matures.

2. Chem-Med's Net Income Growth in 2015

To examine the net income growth, we refer to the net income figures for Chem-Med which were $766,000 in 2014, up from a net income of $101,000 in 2013:

Net Income Growth Rate = [(Net Income Year 2 - Net Income Year 1) / Net Income Year 1] x 100%

Net Income Growth Rate = [(1,150 - 766) / 766] x 100% = 50.20%

Looking forward, the projected net income growth is expected to be about 30% for 2016, reducing to 25% in 2017 and 20% in 2018. Notably, this indicates that projected net income is growing at a faster rate than projected sales, suggesting improving efficiency and profitability as Chem-Med scales.

3. Current Ratio Comparison

The current ratio for Chem-Med in 2015 can be calculated using total current assets and current liabilities. With total current assets of $2,261,000 and total current liabilities of $647,000:

Current Ratio = Total Current Assets / Total Current Liabilities

Current Ratio = 2,261 / 647 = 3.49

Comparatively, Pharmacia had a current ratio of 2.8, above the industry average of 2.4. Chem-Med’s projected current ratio for 2018, if we keep trends in check, is expected to remain healthy, likely around 2.8, marking it well above the conservative benchmark.

4. Debt-to-Assets Ratio Analysis

To determine Chem-Med's total debt-to-assets ratio for 2015, we note that total liabilities were $664,000, and total assets were $2,223,000:

Debt-to-Assets Ratio = Total Liabilities / Total Assets

Debt-to-Assets Ratio = 664 / 2,223 = 0.30

This indicates that Chem-Med maintained a ratio in line with acceptable industry limits, yet as we project out to 2018, with rising assets and manageable debt, we can anticipate a slightly declining debt-to-assets ratio suggesting improved financial stability.

5. Average Accounts Receivable Collection Period

The accounts receivable collection period provides insights into the efficiency of Chem-Med's credit policies. Given that total revenue isn’t separately disclosed in the balance sheet but derived from sales, we would estimate collection days based on the average accounts receivable balance. Assuming balanced accounts receivable at $1,351,000 and known annual sales, we can derive:

Average Collection Period = (Accounts Receivable / Total Sales) x 365

Calculating for 2015:

Average Collection Period (2015) = (1,351,000 / 3,814,000) x 365 ≈ 130.68 days

A shorter period is preferable; if this period is lengthening across 2015-2018, it may point to collection inefficiencies that impact cash flow.

6. Return-on-Equity (ROE) Comparison

The return on equity can be calculated using the Du Pont formula. For Chem-Med in 2015, with net income at $766,000 and shareholder equity computed at approximately $1,331,000:

ROE = (Net Income / Sales) x (Sales / Total Assets) x (Total Assets / Equity)

For Chem-Med's ROE calculation:

ROE = (766 / 3,814) x (3,814 / 2,223) x (2,223 / 1,331) ≈ 0.25

This is favorably comparable to Pharmacia's, which maintains a significant advantage with a calculated ROE of around 19% for the same year, emphasizing the need for Chem-Med to explore efficiency and performance improvement strategies to enhance profitability.

References

  • McGraw Hill Education. (2017). Chem-Med Case Study.
  • Dun’s Industry Ratios. (2015). Biotechnology Sector Analysis.
  • Harvard Business Review. (2016). Financial Management Strategies in Biotech.
  • Investopedia. (2023). Return on Equity (ROE).
  • MarketLine. (2015). Global Biotechnology Industry Profile.
  • IBISWorld. (2023). Industry Risk Ratings: Biotechnology.
  • Mackey, A., & Levin, E. (2022). Investment Strategies in Emerging Industries.
  • SEC.gov. (2023). Guidelines for Reporting Financial Statements.
  • Grossman, S. (2019). Effective Debt Management in Biotechnology.
  • CFA Institute. (2021). Analysis of Financial Statements in Equity Valuation.

Related Assignments